Abstract

Proteoglycans (PGs) are a family of molecules that undergo extensive post-translational modifications that include addition of glycosaminoglycan (GAG) chains as well as N- and O-linked oligosaccharides to the protein core. PG composition and structure have been reported to alter with age. To test whether the post-translational modifications to PGs can serve as in vitro surrogate end point markers for chronological age, the extent of GAG modifications was determined for PGs derived from normal human bone cells of 14 donors (age range, fetal to 60 years). Isolated cells were steady state radiolabeled with (35)SO(4)(2-) and [(3)H]GlcN. For biglycan and decorin, iduronate content was linearly correlated with age (increased 1.5x between fetal and age 60 years). For the syndecan-like heparan sulfate PG, the N-sulfation of post-natal cells increased over 3.5-fold until reaching a plateau during the 4th decade of life. The amount of O-linked oligosaccharides was also found to decrease as a function of increasing normal donor age, whereas the specific activity of the metabolic precursor pool remained constant regardless of donor age. These age-related changes in post-translational modifications were then used to demonstrate that osteoblasts derived from patients with osteogenesis imperfecta did not exhibit facets of a pre-mature aging, but rather were arrested in a fetal-like phenotypic state. A growth matrix rich in thrombospondin altered PG metabolism in osteoblastic cells, resulting in the production and secretion of the fetal-like (rich in O-linked oligosaccharides) forms of decorin and biglycan. This effect was qualitatively different from the effect of transforming growth factor-beta, which predominantly altered GAGs rather than O-linked oligosaccharides. No other Arg-Gly-Asp protein (fibronectin, vitronectin, type I collagen, osteopontin, and bone sialoprotein) showed any detectable effect on PG metabolism in bone cells. These results indicate that a proper matrix stoichiometry is critical for metabolism of PGs.

Highlights

  • From the ‡Dental Research Center, School of Dentistry, University of North Carolina, Chapel Hill, North Carolina 275997455, ¶Division of Geriatric Medicine and Gerontology, the Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, ʈOsteogenesis Imperfecta Program, Kennedy Krieger Institute, the **Department of Orthopedics, The Johns Hopkins University, Baltimore, Maryland 21205, and §Craniofacial and Skeletal Diseases Branch, NIDCR, National Institutes of Health, Bethesda, Maryland 20892

  • Proteoglycan Distribution—In skin and cartilage, the distribution and structure of PGs change with age (13, 29 –36). To test for such changes in osteoblasts, fingerprint profiles of the four PGs produced by bone cells derived from normal and Osteogenesis imperfecta (OI) donors were analyzed by steady-state radiolabeling and quantifying label incorporation into specific PGs (Fig. 1)

  • For osteoblasts derived from normal donors, the versican-like chondroitin sulfate PG (CSPG) was initially the major PG

Read more

Summary

IMPACT OF OSTEOGENESIS IMPERFECTA*

The amount of O-linked oligosaccharides was found to decrease as a function of increasing normal donor age, whereas the specific activity of the metabolic precursor pool remained constant regardless of donor age These age-related changes in post-translational modifications were used to demonstrate that osteoblasts derived from patients with osteogenesis imperfecta did not exhibit facets of a pre-mature aging, but rather were arrested in a fetallike phenotypic state. The current study was undertaken to determine whether post-translational modifications to PGs can serve as surrogate biochemical markers to define donor chronological age These markers were teoglycan; BGN, biglycan; DCN, decorin; BSA, bovine serum albumin; DMEM, Dulbecco’s modified essential medium; FBS, fetal bovine serum; TGF-␤, transforming growth factor ␤; SAX, strong anion exchange; HPLC, high performance liquid chromatography; GAG, glycosaminoglycan; RGD, arginine-glycine-aspartate

OI type III
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call